Pancreatic Cancer Research

Clinical trialPhase 1Completed

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

A Phase 1/2 Study to Assess the Safety and Antitumor Activity of APL-5125 in Adults With Selected Advanced Solid Tumors

Outcome
Finished, no results posted
Phase
Phase 1
Status
Completed
Study type
Interventional
Start
18 June 2024
Ended
8 July 2026
Enrollment
27 participants
Sites
9
Primary outcomes
Incidence of Treatment Emergent Adverse Events [Safety]; Incidence of dose limiting toxicities [Tolerability] (Phase 1); Determine Recommended Phase 2 Dose (RP2D) levels of APL-5125 in participants with selected advanced solid tumors (Phase 1)
Sponsor type
Industry
Results posted
No
Last update
5 October 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).

Detailed description public domain (ClinicalTrials.gov)

The protocol was structured as a Phase 1/2 study with prespecified progression criteria informed by emerging data. Following completion of treatment for the last patient enrolled in Phase 1, it was determined that advancement to the Phase 2 portion of the protocol will not occur.